{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-080529","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.256060+00:00","generated_at":"2026-06-26T21:28:01.393000+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ORIC discontinues ORIC-101 after Phase 1b failures; cash runway extended to 2H 2024","bullets":["ORIC-101 discontinued after interim Phase 1b analyses showed insufficient activity; median PFS 3.7 months in prostate, 1.9 months in pancreatic cohorts.","Focus shifts to three single-agent Phase 1b programs: ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), ORIC-944 (prostate); initial data expected 1H 2023.","Cash and investments $280.4M as of Dec 31, 2021; cash runway extended into second half of 2024 following ORIC-101 discontinuation.","Q4 2021 R&D expenses $16.7M (vs $12.1M Q4 2020); G&A $6.1M (vs $4.3M); increases driven by program advancement and public company costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-080529","json":"https://secwatch.observer/filing/0001193125-22-080529.json","markdown":"https://secwatch.observer/filing/0001193125-22-080529.md","text":"https://secwatch.observer/filing/0001193125-22-080529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312522080529/0001193125-22-080529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312522080529/d323230d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:28:01.393000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}